RxDoctor Payments Data

David Campanelli, MD

Internal Medicine · New Canton, VANPI 1790763829

Payments from drug & device makers

$632in general payments, 2019–2025

Across 35 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$127
  • AbbVie$105
  • Lilly USA, LLC$81
  • Alkermes, Inc.$63
  • Merck$47
  • GSK$45
  • plus $164 from 8 others

What the payments were for

  • Food & beverage$632100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$632 in reported general payments places this provider in the 70th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$49,378
Medicare patients
212
Services billed
1,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin119$176,026
EliquisApixaban148$173,616
JanuviaSitagliptin Phosphate118$154,634
TrulicityDulaglutide104$103,283
TradjentaLinagliptin61$90,439
MounjaroTirzepatide57$57,540
OzempicSemaglutide35$46,370
FarxigaDapagliflozin Propanediol48$45,313
Breo ElliptaFluticasone/Vilanterol38$36,920
XareltoRivaroxaban31$35,710
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$30,544
Lantus SolostarInsulin Glargine,hum.Rec.Anlog98$21,597
SymbicortBudesonide/Formoterol Fumarate63$21,273
AbrysvoRsv Vacc, Pref A And Pref B/Pf44$13,064
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$11,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Premarin$127$194,071212 claims
Lilly USA, LLCTrulicity, Mounjaro$81$160,823161 claims
MerckJanuvia$47$154,634118 claims
GSKBreo Ellipta, Trelegy Ellipta, Shingrix$45$74,982103 claims
Novo NordiskOzempic$33$46,37035 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in New Canton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →